Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print      Mail a friend

Friday 11 December, 2009

Omega Diagnostics Gp

Trading Statement

RNS Number : 9586D
Omega Diagnostics Group PLC
11 December 2009
 



Omega Diagnostics plc

("Omega" or the "Company")

Trading Update


The Board indicated in the Company's interim results released on 27th November 2009 that additional growth in Genarrayt sales depended on a resolution to improving the method of manufacturing of these slides. The Board has been continually reviewing the capabilities of the non-contact printing system for manufacturing the Genarrayt slides on a consistent basis. However, following a further technical review of the process today the Board has concluded that until the issues with the manufacturing process are fully resolved the Company will revert solely to the previous manufacturing method. Under the previous manufacturing method the number of slides that can be manufactured is lower than using the non-contact printing system. Consequently, the Board now advises that revenue for the year ended 31 March 2010 is expected to be marginally lower than its previous expectations and that there will be a consequential impact on adjusted profit before tax.  


 


Omega Diagnostics Group PLC

Walbrook PR Ltd

Tel: 01259 763 030

Paul McManus



Andrew Shepherd, Chief Executive

Tel: 020 7933 8787

Kieron Harbinson, Finance Director

Mob: 07980 541 893

www.omegadiagnostics.com

paul.mcmanus@walbrookpr.com


Cenkos Securities plc

Nomad and Broker

Nick Wells/Andy Roberts


Tel: 020 7397 8900







This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTZGMMZRGLGLZM